HIGH DOSE APPLICATION OF SPINRAZA TREATMENT WITH NUSINERSEN ACTIVE INGREDIENT USED IN THE TREATMENT OF SMA PATIENTS HAS BEEN APPROVED BY FDA (US FOOD AND DRUG ADMINISTRATION).

There has been a significant development in the treatment of Spinal Muscular Atrophy (SMA).

High dose application of Spinraza, which contains the active ingredient nusinersen, used in the treatment of SMA patients, was approved by the FDA (US Food and Drug Administration). Approved by the administration. With its broad use approval covering all SMA patients, this development is an extremely important step for SMA patients and their relatives.

Nusinersen is a drug that works by increasing the production of the SMN protein, which is critical for the function of motor neurons. is the treatment. High dose application aims to further increase these protein levels.

This approval is in terms of studies conducted for the treatment and management of SMA disease. It represents a significant advance. The potential of high dose application to improve treatment results and increase the quality of life is considered a promising development for SMA patients and their families.

As the Turkish SMA Foundation, we closely follow the current developments in the world; We continue to work with healthcare professionals and all stakeholders to ensure that our patients receive timely information about new treatment options and to support their access processes.

For Resources;
Click Here. 
Click Here.